ARIH2 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population that enables loss-of-function studies of the ARIH2 gene in a human colorectal adenocarcinoma model. This product delivers a heterogeneous pool of HT29 cells carrying distinct disruptions within the target locus, collectively abolishing functional ARIH2 expression without relying on single-cell clonal isolation. By providing a population-level knockout, the model captures the biological variability inherent in gene editing while maintaining robust representation of the parental cell line??s genomic background. The pooled format is particularly suited for experiments that require eliminating ARIH2-dependent activities while minimizing clonal artifacts, and it integrates seamlessly into standard functional genomics workflows.
The parental HT29 cell line is a widely characterized human colon adenocarcinoma model originally derived from a primary tumor in a 44-year-old Caucasian female. These cells retain typical epithelial morphology and harbor genetic lesions commonly found in colorectal cancer, including mutations in APC and TP53, making them a relevant platform for studying tumor biology, epithelial barrier function, and therapeutic responses. HT29 cells are employed extensively in drug screening, signal transduction research, and disease modeling, and their authenticated genetic background ensures reproducibility across independent studies. The polyclonal knockout derivative preserves this well-documented cellular context while introducing a targeted loss of ARIH2.
ARIH2 encodes an E3 ubiquitin ligase that catalyzes ubiquitin transfer from E2 conjugating enzymes, such as UBE2L3, to substrate proteins, thereby regulating their proteasomal degradation or non-proteolytic signaling functions. ARIH2 operates within cullin-RING ligase complexes and physically interacts with TRAF proteins and Parkin, positioning it at the intersection of multiple ubiquitin-dependent pathways. Its activity is stimulated by upstream signals including TNF-alpha, IL-1beta, DNA damage, and pathogen-associated molecular patterns (PAMPs). Downstream, ARIH2 modulates critical effectors such as NF-kappaB transcription factors and the p53 tumor suppressor, coupling ubiquitination dynamics to innate immune responses, inflammatory signaling, and cell cycle checkpoints. In the cellular environment, ARIH2 fine-tunes the amplitude and duration of NF-kappaB activation and influences DNA damage repair pathway choice, thereby shaping cell fate decisions.
In the colorectal cancer setting, disruption of ARIH2 in HT29 cells alters the equilibrium between pro-survival and apoptotic signals governed by NF-kappaB and p53 networks. This perturbation is particularly relevant for dissecting mechanisms of chemoresistance and tumor progression, as colon carcinoma cells frequently exploit ubiquitin-mediated regulation to bypass growth constraints and evade immune surveillance. The polyclonal knockout model enables researchers to examine how ARIH2 loss affects cell proliferation, migration, and cytokine responsiveness in an isogenic background, while also providing a tool to explore the interplay between ARIH2 and inflammatory mediators in epithelial-derived malignancies. Beyond colorectal cancer, this model informs studies on breast cancer, autoimmune disorders, and other pathologies linked to ubiquitin pathway dysregulation.
This polyclonal knockout cell population is suitable for a range of molecular and functional assays, including western blotting, RT-qPCR, cell viability measurements, and ubiquitination analyses. The model supports NF-kappaB luciferase reporter assays to quantify transcriptional activity and scratch wound healing tests to evaluate migration phenotypes. Researchers investigating signaling crosstalk, drug sensitivity, or ubiquitin ligase substrate identification will find these cells a valuable resource. For additional technical information, protocol guidance, or ordering inquiries, please contact Ascent Research.
